Drug Use Investigation of EOB-Primovist Inj. Syringe
N/A
N/A
N/A
N/A
N/A
Not Enrolling
Both
Diagnostic Imaging
Both
Diagnostic Imaging
Trial Information
Drug Use Investigation of EOB-Primovist Inj. Syringe
Inclusion Criteria:
- Patients who received Primovist for liver MRI
Exclusion Criteria:
- Patients who are contraindicated based on the product label
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Prospective
Outcome Measure:
Incidence of adverse drug reactions and serious adverse events in subjects who received Primovist
Outcome Time Frame:
After Primovist injection, up to 7 days
Safety Issue:
Yes
Principal Investigator
Bayer Study Director
Investigator Role:
Study Director
Investigator Affiliation:
Bayer
Authority:
Japan: Ministry of Health, Labor and Welfare
Study ID:
15040
NCT ID:
NCT01411449
Start Date:
March 2008
Completion Date:
December 2010
Related Keywords:
- Diagnostic Imaging
- Primovist
- MRI agent
Name | Location |
|---|
